French Probe Possibility Of Manslaughter In Phase I Trial Case
This article was originally published in The Pink Sheet Daily
Review will consider whether study fatality and serious injuries were a matter of "scientific chance" or "faults of a criminal nature"; separate evaluations will inform guidelines on first-in-human trials.
You may also be interested in...
Brexit vote creates uncertainty about biopharma policies in the UK and how local companies interact with the rest of the world;; antibiotic use decreases in several countries; high prices prompt European Commission review of industry incentives.
European Notebook: All Change In The C-Suites; EMA PRIME Starts; French Experts Recommend Phase I Changes
Once-in-a-decade leadership changes stack up in Europe’s big pharma companies as the region aims for quicker and more certain drug development, although following a recent fatality an expert committee is advising caution during dose-escalation in Phase I studies.
European Notebook: Clinical Trial Fatality; Affordable Medicines Debate; Physician Payment Disclosure
One death and five healthy volunteers hospitalized in a Phase I study in France; EU Council looks set to debate patient access to medicines; and the two Mercks set to continue litigation in Europe and the US over use of the Merck word, straining their 60-year-old agreement. Generics/biosimilar trade group adopts physician payment disclosure policy.